1-3 of 3
Huangling Zhu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-Phase chronic myeloid leukemia (CML-CP) in a registrational randomized Phase 2 trial: Up to 4-year follow-up including patients without T315I mutations

Free
Qian Jiang, Zongru Li, Yanli Zhang, Yu Hu, Weiming Li, Yongping Song, Junmin Li, Li Zhou, Bingcheng LIU, Xiaoli Liu, Na Xu, Suning Chen, Zhenfang LIU, Huangling Zhu, Jie Jin, He Huang, Sixuan Qian, Li Meng, Xin Du, Xielan Zhao, Sujun Gao, Yang Liang, Ming Hou, Wei Wang, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2025) 146 (Supplement 1): 3788.
https://doi.org/10.1182/blood-2025-3788
Published: 2025
Journal Articles

Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients (pts) with chronic Phase-chronic myeloid leukemia (CP-CML)

Free
Li Weiming, Yanli Zhang, Huangling Zhu, Yunfan Yang, Na Xu, Bingcheng LIU, Fang Cheng, Zi Chen, Wei Chu, Yifan Zhai, Yu Hu
Journal: Blood
Blood (2025) 146 (Supplement 1): 3782.
https://doi.org/10.1182/blood-2025-3782
Published: 2025
Journal Articles

The Difference of Macrophage Involvement in Multiple Myeloma Patients with Distinct Prognosis

Free
Wu Yu, MD & PhD, Huangling Zhu, MD, Li Xiang Long, Ting Liu, MD
Journal: Blood
Blood (2012) 120 (21): 4979.
https://doi.org/10.1182/blood.V120.21.4979.4979
Published: 2012